Rare mendelian disorders are being characterized with increasing success owing to the rapid development of tools for defining phenotypic and genetic determinants. The elucidation of disease pathogenesis may simultaneously trigger the identification of pathway-specific treatment targets, but the development of disease-modifying medications is often hampered by the fragmentation of efforts and the low number of available patients. The integration of scattered resources is, therefore, crucial for the success of future scientific accomplishments. Here we report the inception of a central data repository for a group of rare disorders collectively called Neurodegeneration with Brain Iron Accumulation (NBIA).

NBIA has an estimated prevalence of 1--3 / 10^6^ and consists of several genetically-defined entities that clinically often overlap but also have unique features (Table [1](#T1){ref-type="table"}). The neuropathological hallmarks include iron accumulation associated with neuronal loss and gliosis, which appear as hypointense lesions (iron) with or without hyperintense patches (gliosis) on T2-weighted MRI in most NBIA forms. The "eye of the tiger" sign (a hypointense area with a hyperintense center) in the globus pallidus is seen in Pantothenate Kinase-Associated Neurodegeneration (PKAN) ( \[[@B1]\]). Iron in the brain can be assessed by using dual spin-echo and multiple gradient-echo MRI sequences, which allow monitoring an endophenotype of the disease. Biological heterogeneity of NBIA is reflected by the differential appearance of various neuronal inclusions in the genetically defined sub-entities. However, shared functions of the affected genes are also recognized in the maintenance of membrane phospholipids and the regulation of mitochondrial energy metabolism, explaining the degenerative features of neuropathology ( \[[@B2]\]). Even though the excess of iron appears pathogenic, molecular causes and consequences of its accumulation remain unknown. An iron-chelating agent, deferiprone, approved for systemic iron-overload disorders, is currently being tested in the largest subgroup of NBIA, PKAN (Table [1](#T1){ref-type="table"}). This deferiprone trial with the associated biobank and patient registry represent core work packages in TIRCON (Treat Iron-Related Childhood-Onset Neurodegeneration), an international consortium supported by the European CommissionÂ´s Seventh Framework Programme.

###### 

NBIA disorders

  **Disease**                                                                           **Gene**        **Inheritance**       **Clinical presentation**                                                                                                                                                                                                                            **MRI**
  ------------------------------------------------------------------------------------- --------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  **Classic form:** Early onset -- rapid progression                                                                                                                                                                                                                                                                                                                               
  Pantothenate kinase-associated neurodegeneration (PKAN)                               *PANK2*         autosomal recessive   Gait abnormality, dystonia, dysarthria, corticospinal involvement, pigmentary retinopathy                                                                                                                                                            "Eye-of-the-tiger" sign in the GP
  Mitochondrial membrane protein-associated neurodegeneration (MPAN)                    *C19orf12*      autosomal recessive   Speech and gait difficulties, progressive spastic paraparesis, dystonia, optic atrophy, axonal motor neuropathy, cognitive decline                                                                                                                   Increased iron in GP and SN; "Eye of the tiger" sign very rare
  Fatty-acid hydroxylase-associated neurodegeneration (FAHN)                            *FA2H*          autosomal recessive   Onset with focal dystonia and gait impairment, ataxia, dysarthria, spastic quadriparesis, nystagmus, visual loss, no or mild cognitive impairment and seizures in late stages; overlaps with some HSP syndromes and phenotypes of leukodystrophies   Abnormal iron in GP and SN, optic, cerebellar and brainstem atrophy, confluent subcortical and periventricular hyperintensity, thinning of the CC
  PLA2G6-associated neurodegeneration (PLAN) --Infantile neuroaxonal dystrophy (INAD)   *PLA2G*         autosomal recessive   Severe psychomotor regression, hypotonia, peripheral motor neuropathy, hyperreflexia, tetraparesis, ataxia, gait abnormalities                                                                                                                       Cerebellar atrophy, abnormal iron in GP and other nuclei
  **Atypical form:** Later onset -- slower progression                                                                                                                                                                                                                                                                                                                             
  Atypical pantothenate kinase-associated neurodegeneration (PKAN)                      *PANK2*         autosomal recessive   Speech abnormalities, depression, impulsivity, aggression, emotional instability                                                                                                                                                                     Eye-of-the-tiger sign or variants of it in the GP or other signs of increased iron and gliosis in the GP
  Atypical mitochondrial membrane protein-associated neurodegeneration (MPAN)           *C19orf12*      autosomal recessive   Psychiatric features, parkinsonism, dystonia-parkinsonism, motor axonal neuropathy, mild gait difficulty, optic atrophy, cognitive decline                                                                                                           Increased iron in GP and SN
  Neuroferritinopathy                                                                   *FTL*           autosomal dominant    HuntingtonÂ´s disease-like presentation: adult-onset chorea or dystonia, orofacial action dystonia, cognitive decline                                                                                                                                Abnormal iron and later cystic changes in the basal ganglia
  Aceruloplasminemia                                                                    *CP*            autosomal recessive   Diabetes mellitus, retinal degeneration, blepharospasm, facial and neck dystonia, chorea, tremor, dysarthria, ataxia -- typically adult onset                                                                                                        Pathological iron in both the brain and viscera; in the brain: GP, striatum, thalami, dentate nuclei
  In the viscera: liver                                                                                                                                                                                                                                                                                                                                                            
  PLA2G6-associated neurodegeneration (PLAN) --neuroaxonal dystrophy (NAD)              *PLA2G6*        autosomal recessive   Progressive dystonia, dysarthria, language delay, corticospinal signs, psychiatric features and social difficulties or similar to but later onset version of INAD                                                                                    Cerebellar and optic nerve atrophy
  Iron may or may not be increased                                                                                                                                                                                                                                                                                                                                                 
  PLA2G6-associated neurodegeneration (PLAN) -- dystonia-parkinsonism                   *PLA2G6*        autosomal recessive   Parkinsonism, dystonia-parkinsonism                                                                                                                                                                                                                  Iron may be increased in SN an striatum
  **Other NBIA form**                                                                                                                                                                                                                                                                                                                                                              
  Kufor-Rakeb syndrome                                                                  *ATP13A2*       autosomal recessive   Juvenile onset parkinsonism, corticospinal signs, supranuclear gate palsy and cognitive decline, facial-faucial-finger myoclonus, visual hallucinations, oculogyric crisis                                                                           Generalized brain atrophy, increased iron in the caudate and lenticular nuclei, but increased iron is not always present
  Woodhouse-Sakati Syndrome                                                             *C2orf37*       autosomal recessive   Hypogonadism, diabetes, alopecia, hearing loss, mental retardation, progressive generalized and focal dystonia, dysarthria, cognitive decline                                                                                                        Increased iron in GP, SN and other nuclei; white matter abnormalities
  Static Encephalopathy with Neurodegeneration in Adulthood (SENDA)                     *In progress*   autosomal recessive   Childhood onset cognitive impairment without progression; in adult age sudden onset progressive dystonia-parkinsonism and corticospinal signs.                                                                                                       Increased iron in the GP and SN; on T1W MRI, hyperintensity with central band of hypointensity in the SN; cerebral and cerebellar atrophy

Legend to Table.

The table summarizes the currently known entities collected under the umbrella of NBIA. Transitional phenotypes are increasingly observed within the spectrum between the extremes of the early and late onset forms due to the routine use of molecular genetics in clinical practice.

Increased iron in the brain is reflected by hypointensity on T2-weighted MRI scans, and is typically detected in nuclei where some iron is normally present: GP, SN, putamen, caudate, dentate nuclei and red nuclei. The "eye of the tiger" sign refers to an ovoid area of hypointensity with a hyperintense center corresponding to increased iron and gliosis, respectively, within the GP. The histological substrates of iron accumulation include the astrocytes, microglia / macrophages, neurons, neuropil and the perivascular space. In the same regions, axonal spheroids, neuronal loss, gliosis and demyelination may also be present. Ceroid lipofuscin and neuromelanin may accumulate intracellularly and extracellularly. The numbers of histopathological studies on genetically defined subentities are limited, but so far have revealed a differential occurrence of various neuronal inclusions.

GP: Globus pallidus.

SN: Substantia nigra.

CC: Corpus callosum.

T1W MRI: T1-weighted magnetic resonance imaging.

T2W MRI: T2-weighted magnetic resonance imaging.

NA: not available.

As a central data repository of TIRCON, the NBIA registry ( <http://www.tirconregistry.org>) manages links to the deferiprone trial database, the NBIA image archive and biobank. The collected information includes demographics, family and patient history, clinical signs, neurological exam, laboratory results, brain iron assessment and volumetry by imaging, treatments and trials. The disease course is captured by standardized scales measuring dystonia severity, quality of life and sleep, functional independence, cognition, motor functioning and activity of daily living. The annually entered information enables a longitudinal reconstruction of the disease course, while genomic, transcriptomic, proteomic and metabolomic data from research on the biobank specimens contribute additional dimensions to the registry.

The technical development of the registry involved significant preparatory works. During an initial phase of six months, existing local databases and their datasets were analysed in order to specify data elements which are harmonized and most useful for the international NBIA registry. For quick and easy data entry by participating clinicians, web-based forms have been created. Management of directly identifying data are restricted to the respective sites, and only patient codes (pseudonyms) will be entered into the registry database. Together with these patient pseudonyms, codes identifying biospecimens, images, and data in the deferiprone trial database are kept in the registry and safeguarded by a sophisticated security and privacy architecture.

The registry's security and privacy concept builds upon the security architecture of the German mitoNET repository ( \[[@B3]\]), which has been successfully running for more than three years. Access rights are strictly role-based, and pseudonyms are kept spatially and organizationally separate from the registry database storing medical/research data. Double coding is used for all pseudonyms, which are additionally secured by encryption. In terms of the US Health Insurance Portability and Accountability Act, protected health information compliant with the "limited data set" definition is stored.

For the use of data and biosamples, agreements have been specified and approved by local ethics committees and data protection authorities. Future research proposals will be reviewed by the TIRCON's Scientific Steering Committee (SSC). If the proposal is approved, pseudonymous or anonymous data will be released to the future investigator, depending on the proposal and the vote of the SSC. As an additional safeguard, re-identification attempts are prohibited by the data use agreements.

In summary, this registry longitudinally collects multi-dimensional information on NBIA disorders to provide a rich resource for future natural history studies, evaluations of clinical and paraclinical surrogates or potential predictors of the disease, and correlation analyses of clinical subentities with pathogenic mutations, alleles of disease modifying genes, results of "-omics" and environmental factors. It will support the design of placebo-controlled, randomized, double-blind clinical trials, and allow probing which clinical, imaging or laboratory features of the disease may be modified by a treatment modality. The NBIA registry represents a paradigm fostering integration of international resources for the enhancement of scientific synergism and future research activities in a group of rare diseases.
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